Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:40:18 2026-05-13 EDT			5-day change	1st Jan Change
113.04 ^USD	+0.60%		-0.69%	+6.75%

05-12	Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026	RE
05-12	Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026	CI

Press Releases

05-12	Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026	BU
05-08	Merck : Statement on Daiichi Sankyo Update to Manufacturing and Supply Plan - Merck.com	PU
05-07	Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate	BU
05-05	Merck Completes Acquisition of Terns Pharmaceuticals, Inc.	BU
04-30	Merck : Icon 1Q26 Merck Earnings Announcement	PU
04-30	Merck : Icon 1Q26 Merck Earnings Presentation	PU
04-30	Merck: Q1 Earnings Snapshot	AQ
04-30	Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones	BU
04-28	Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke	BU
04-27	Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.	AQ
04-24	Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.	BU
04-22	Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation	PR
04-21	FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)	BU
04-21	Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)	BU
04-20	FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer	BU
04-17	European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season	BU
04-15	New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada	AQ
04-13	Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy	BU
04-13	Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy	BU
04-07	Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.	BU
04-02	Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration	BU
04-02	European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens	BU
04-01	Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30	BU
03-30	Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins	BU
03-30	Merck - Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR in Adults with the Syndrome of Combined Post and Precapillary Pulmonary Hypertension and Heart Failure	AQ